1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, March 2017 (p5)

Cancer Analysis & Statistics in European Union, March 2017 (p5)

121-139 of about 100 reports

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017

Disease OverviewLung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016SummaryGlobal Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative ...

  • Industries : Pathology, Therapy, Pharmaceutical
  • Countries : World, European Union, Japan, United States
Gastric cancer

Gastric cancer

  • $ 5000
  • Industry report
  • July 2016

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.This report addresses the following questions:- ...

  • Industries : Cancer, Pathology
  • Countries : Japan, United States, East Asia, European Union, North America, Europe
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016

  • $ 3500
  • Company report
  • June 2016

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016SummaryGlobal Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative ...

  • Industries : Therapy, Pathology, Pharmaceutical
  • Countries : World, United States, Japan, European Union
Head and neck cancer

Head and neck cancer

  • $ 5000
  • Industry report
  • June 2016

Revenues from new brands will offset the biosimilar and generic erosion of Erbitux and TS-1, enabling the net growth of the head and neck cancer market.This report addresses the following questions: - ...

  • Industries : Health Services, Healthcare, Therapy
  • Countries : United States, Japan, European Union, East Asia, North America, Europe
Chronic myeloid leukemia

Chronic myeloid leukemia

  • $ 5000
  • Industry report
  • May 2016

Sprycel and Tasigna continue to compete for market share in second-line CML as generic imatinib begins to supersede Gleevec in all markets.This report addresses the following questions:- What are the ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Breast cancer: triple - negative

Breast cancer: triple - negative

  • $ 5000
  • Industry report
  • May 2016

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.This report addresses the following ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia
NHL: Diffuse large Bcell lymphoma

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • Industry report
  • May 2016

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016–25 ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Chemotherapy induced anemia

Chemotherapy induced anemia

  • $ 5000
  • Industry report
  • April 2016

The chemotherapy-induced anemia (CIA) market is expected to grow marginally due to a lack of novel therapies and a static disease population.This report addresses the following questions:- How have developments ...

  • Industries : Pathology, Therapy, Oncology, Healthcare
  • Countries : United States, Japan, European Union, North America, Europe, East Asia
Pancreatic cancer

Pancreatic cancer

  • $ 5000
  • Industry report
  • April 2016

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies.This report addresses the ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Acute lymphoblastic leukemia

Acute lymphoblastic leukemia

  • $ 5000
  • Industry report
  • April 2016

The entry of CAR-T therapies will offset the generic erosion of the TKI class to drive huge growth in the acute lymphoblastic leukemia (ALL) market.This report addresses the following questions:- In which ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
NHL: Follicular lymphoma

NHL: Follicular lymphoma

  • $ 5000
  • Industry report
  • April 2016

The follicular lymphoma (FL) market will continue to grow during 2016–25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies.This ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
Colorectal cancer

Colorectal cancer

  • $ 5000
  • Industry report
  • April 2016

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market.This report addresses the following questions: - ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, North America, Japan, Europe, East Asia
Renal cell cancer

Renal cell cancer

  • $ 5000
  • Industry report
  • April 2016

Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents.This ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union, North America, East Asia, Europe
NHL: Mantle cell lymphoma

NHL: Mantle cell lymphoma

  • $ 5000
  • Industry report
  • April 2016

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016–25.This report ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia
Hepatocellular cancer

Hepatocellular cancer

  • $ 5000
  • Industry report
  • April 2016

The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market.This report addresses the following questions:- ...

  • Industries : Pathology, Cancer
  • Countries : Japan, United States, European Union, East Asia, North America, Europe
Breast cancer: HR+/HER2-

Breast cancer: HR+/HER2-

  • $ 5000
  • Industry report
  • April 2016

Ibrance’s continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.This report addresses the following questions:- Which branded therapies ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan, North America, Europe, East Asia
Prostate cancer

Prostate cancer

  • $ 5000
  • Industry report
  • February 2016

The value of the prostate cancer market will more than double during 2015–24, reaching $13.5bn in 2024 at a compound annual growth rate (CAGR) of 8.6%.This report addresses the following questions:- ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, North America, Europe, Japan, East Asia
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

  • $ 1077
  • Industry report
  • January 2016

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : European Union, United States

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on